Positive News SentimentPositive NewsNASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free MIST Stock Alerts $1.70 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.67▼$1.7450-Day Range$1.42▼$1.8352-Week Range$1.33▼$4.49Volume36,354 shsAverage Volume165,599 shsMarket Capitalization$90.36 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Milestone Pharmaceuticals alerts: Email Address Milestone Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside532.4% Upside$10.75 Price TargetShort InterestHealthy0.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector488th out of 925 stocksPharmaceutical Preparations Industry223rd out of 430 stocks 3.4 Analyst's Opinion Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.81% of the outstanding shares of Milestone Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently decreased by 0.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MIST. Previous Next 2.7 News and Social Media Coverage News SentimentMilestone Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Milestone Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.15) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Milestone Pharmaceuticals Stock (NASDAQ:MIST)Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Read More MIST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIST Stock News HeadlinesMay 2, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024April 17, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumMay 12, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 17, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumApril 8, 2024 | finance.yahoo.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 8, 2024 | globenewswire.comMilestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingApril 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceApril 1, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual ConferencesMay 12, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 28, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular TachycardiaMarch 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)March 21, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy RecommendationMarch 21, 2024 | investorplace.comMIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023March 21, 2024 | globenewswire.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate UpdateFebruary 29, 2024 | globenewswire.comMilestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsFebruary 28, 2024 | marketwatch.comMilestone Pharma Shares Drop After Public Offering NewsFebruary 28, 2024 | msn.comMilestone Pharmaceuticals launches stock and warrants offeringFebruary 28, 2024 | globenewswire.comMilestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsFebruary 26, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial OutlookFebruary 26, 2024 | msn.comWhy Milestone Pharmaceuticals (MIST) Stock Is RisingFebruary 26, 2024 | finance.yahoo.comMilestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVTFebruary 21, 2024 | benzinga.comMilestone Pharmaceuticals Stock (NASDAQ:MIST) Insider TradesFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA ApprovalFebruary 11, 2024 | finance.yahoo.comMilestone Pharmaceuticals Inc. (MIST)January 31, 2024 | reuters.comNovartis eyes 5% annual sales growth through 2028January 25, 2024 | businesswire.comDr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist TechnologySee More Headlines Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIST CUSIPN/A CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees47Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+532.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,690,000.00 Net MarginsN/A Pretax Margin-5,968.50% Return on Equity-170.99% Return on Assets-64.45% Debt Debt-to-Equity Ratio2.97 Current Ratio10.11 Quick Ratio10.11 Sales & Book Value Annual Sales$1 million Price / Sales90.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book3.40Miscellaneous Outstanding Shares53,150,000Free Float47,622,000Market Cap$90.36 million OptionableOptionable Beta1.77 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joseph G. Oliveto M.B.A. (Age 56)CEO, President & Director Comp: $905.71kMr. Amit Hasija (Age 51)CFO & Executive VP of Corporate Development Comp: $603.18kDr. David B. Bharucha FACC (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $440.67kDr. Philippe Douville M.B.A. (Age 62)Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board Mr. Jeff Nelson (Age 43)Chief Operating Officer Ms. Kim FoxVice President of CommunicationsDr. Philip T. Sager FACC (Age 68)FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board Dr. Guy RousseauSVP of Regulatory Affairs and Quality ManagementMs. Anita HolzVP & Head of Medical AffairsMore ExecutivesKey CompetitorsAnixa BiosciencesNASDAQ:ANIXProPhase LabsNASDAQ:PRPHOncolytics BiotechNASDAQ:ONCYAclaris TherapeuticsNASDAQ:ACRSSpero TherapeuticsNASDAQ:SPROView All CompetitorsInstitutional OwnershipBNP Paribas Financial MarketsBought 10,800 shares on 5/1/2024Ownership: 0.032%Clear Creek Financial Management LLCSold 6,750 shares on 4/26/2024Ownership: 0.047%BML Capital Management LLCBought 163,793 shares on 4/23/2024Ownership: 1.140%View All Institutional Transactions MIST Stock Analysis - Frequently Asked Questions Should I buy or sell Milestone Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MIST shares. View MIST analyst ratings or view top-rated stocks. What is Milestone Pharmaceuticals' stock price target for 2024? 4 analysts have issued 12 month target prices for Milestone Pharmaceuticals' shares. Their MIST share price targets range from $4.00 to $25.00. On average, they predict the company's stock price to reach $10.75 in the next year. This suggests a possible upside of 532.4% from the stock's current price. View analysts price targets for MIST or view top-rated stocks among Wall Street analysts. How have MIST shares performed in 2024? Milestone Pharmaceuticals' stock was trading at $1.67 at the start of the year. Since then, MIST shares have increased by 1.8% and is now trading at $1.70. View the best growth stocks for 2024 here. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Thursday, March, 21st. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX). When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Milestone Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (1.14%), Clear Creek Financial Management LLC (0.05%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include David Bharucha, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIST) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
